VENATORX PHARMACEUTICALS, INC.

Company Information

Company Name
VENATORX PHARMACEUTICALS, INC.
Address
30 Spring Mill Drive
Malvern, PA, 19355-1200
Phone
n/a
URL
n/a
DUNS
962754037
Number of Employees
18

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$2,399,200.00
4
SBIR Phase II
$6,000,000.00
2
Chart code to be here

Award List

  1. Novel Metallo-beta-lactamase Inhibitors

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as ...

    SBIR Phase I 2011 Department of Health and Human Services
  2. Preserving beta-lactam utility against pathogens producing all classes of beta-la

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Novel Compounds Targeting Bacterial PBPs

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiot ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. While carbapenems are among the most prescribed antibiotics for infections caused b ...

    SBIR Phase II 2013 Department of Health and Human Services
  5. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. This crisis has been further amplified by the recent emergence of the NDM-1 su ...

    SBIR Phase II 2013 Department of Health and Human Services
  6. Broad-spectrum, orally-bioavailable beta-lactamase inhibitors

    Amount: $599,200.00

    DESCRIPTION (provided by applicant): Broad-spectrum, orally bioavailable -lactam antibiotics play a critical role in the management of human infectious diseases, both in the hospital and community se ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government